NEW YORK, NY / ACCESSWIRE / October 23, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
Blink Charging Company (NASDAQ: BLNK)
CONTACT JAKUBOWITZ ABOUT BLNK:
https://claimyourloss.com/securities/blink-charging-company-loss-submission-form/?id=10410&from=1
Class Period : March 6, 2020 - August 19, 2020
Lead Plaintiff Deadline : October 23, 2020
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) many of Blink's charging stations are damaged, neglected, non-functional, inaccessible, nor non-accessible; (ii) Blink's purported partnerships and expansions with other companies were overstated; (iii) the purported growth of the Company's network has been overstated; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
CONTACT JAKUBOWITZ ABOUT BMRN:
https://claimyourloss.com/securities/biomarin-pharmaceutical-inc-loss-submission-form/?id=10410&from=1
Class Period : February 28, 2020 - August 18, 2020
Lead Plaintiff Deadline : November 24, 2020
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec, an investigational adenoassociated virus gene therapy, limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec's durability of effect; (ii) as a result, it was foreseeable that the U.S. Food and Drug Administration would not approve the Biologics License Application for valoctocogene roxaparvovec without additional data; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
Peabody Energy Corporation (NYSE: BTU)
CONTACT JAKUBOWITZ ABOUT BTU:
https://claimyourloss.com/securities/peabody-energy-corporation-loss-submission-form/?id=10410&from=1
Class Period : April 3, 2017 - October 28, 2019
Lead Plaintiff Deadline : November 27, 2020
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) the Company had failed to implement adequate safety controls at the North Goonyella mine to prevent the risk of a spontaneous combustion event; (b) the Company failed to follow its own safety procedures; (c) as a result, the North Goonyella mine was at a heightened risk of shutdown; (d) the Company's low-cost plan to restart operations at the mine posed unreasonable safety and environmental risks; (e) The Australian body responsible for ensuring acceptable health and safety standards, the Queensland Mines Inspectorate, would likely mandate a safer, cost-prohibitive approach; and (f) as a result, there would be major delays in reopening the North Goonyella mine and restarting coal production.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE: Jakubowitz Law